235
Participants
Start Date
June 30, 2006
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
exenatide
subcutaneous injection, 5mcg or 10mcg, twice a day
insulin glargine
subcutaneous injection, titrated to target blood glucose level, once a day
Research Site, Aberdeen
Research Site, Bath
Research Site, Blackburn
Research Site, Bolton
Research Site, Bournemouth
Research Site, Bristol
Research Site, Chippenham
Research Site, Edinburgh
Research Site, Glasgow
Research Site, Haywards Heath
Research Site, High Wycombe
Research Site, Hull
Research Site, Ipswich
Research Site, Kent
Research Site, Leicester
Research Site, Liverpool
Research Site, Livingstone
Research Site, London
Research Site, Manchester
Research Site, Metropolitan Borough of Wirral
Research Site, Middlesbrough
Research Site, Norwich
Research Site, Nottingham
Research Site, Oldham
Research Site, Oxford
Research Site, Plymouth
Research Site, Rochdale
Research Site, Salford
Research Site, Swansea
Research Site, Torquay
Research Site, Wakefield
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY